<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521179</url>
  </required_header>
  <id_info>
    <org_study_id>KN026-203</org_study_id>
    <nct_id>NCT04521179</nct_id>
  </id_info>
  <brief_title>Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and&#xD;
      tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping&#xD;
      epitopes of HER2, leading to a dual HER2 signal blockade.KN046 is a PD-L1 - CTLA-4 bispecific&#xD;
      antibody. The study composes of two stages. The first stage plans to enroll HER2-positive&#xD;
      solid tumors. All subjects will be treated with KN026 at 30 mg/kg Q3W in combination with&#xD;
      KN046 at 5 mg/kg Q3W at the first stage.A SMC meeting will decide whether to proceed to the&#xD;
      nest stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR )</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
    <description>Objective response rate as assessed by the investigator according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
    <description>Duration of response (DOR) as assessed by the investigator according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Progression free survival (PFS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>CBR calculated as the proportion of subjects with best overall response of CR, PR, or SD ≥24 weeks</time_frame>
    <description>Clinical benefit rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Overall survival (OS) rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HER2-positive Solid Tumors</condition>
  <arm_group>
    <arm_group_label>KN026 combined with KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 combination</intervention_name>
    <description>30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046</description>
    <arm_group_label>KN026 combined with KN046</arm_group_label>
    <other_name>IO therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject &gt;= 18 years;&#xD;
&#xD;
          -  Histologically or cytologically confirmed, metastatic or locally advanced unresectable&#xD;
             HER2-positive solid tumors;&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  Life expectancy &gt;3 months;&#xD;
&#xD;
          -  Baseline measurable disease according to RECIST 1.1 as determined by the local site&#xD;
             investigator/radiology assessment;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either&#xD;
             ECHO (preferred) or MUGA;&#xD;
&#xD;
          -  Able to understand, voluntarily participate and willing to sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated active brain metastasis or leptomeningeal metastasis;&#xD;
&#xD;
          -  History of Left ventricular ejection fraction (LVEF) decline to &lt; 45% or absolute&#xD;
             decrease for &gt; 15% during the treatment course from prior HER2-targeted therapy;&#xD;
&#xD;
          -  Has received other anti-tumor treatment or an investigational drug within 28 days&#xD;
             prior to the first trial treatment;&#xD;
&#xD;
          -  Major surgery for any reason within 28 days ;&#xD;
&#xD;
          -  Prior allo-HSCT or solid organ transplant;&#xD;
&#xD;
          -  Pregnant or nursing females;or intend pregnancy within this study period or within 6&#xD;
             months after the end of this study;&#xD;
&#xD;
          -  Other medical conditions that at the discretion of investigator interfere with the&#xD;
             requirements of the trial in terms of safety or efficacy evaluation, or treatment&#xD;
             compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jifang Gong, professor</last_name>
    <phone>0086-10-88196391</phone>
    <email>goodjf@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, MD,PhD</last_name>
      <phone>010-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KN026 and KN046</keyword>
  <keyword>HER2-Positive Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

